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 CURRENTOPINION Mechanical circulatory support challenges in
pediatric and (adult) congenital heart disease
Martin Schweigera, Angela Lortsb, and Jennifer Conwayc
Purpose of review
Increased miniaturization of ventricular assist devices (VADs) and new mechanical support strategies (MCS)
has increased the use of MCS in the pediatric and congenital heart disease (CHD) population. This comes
with the need for care providers specialized in this field to determine optimal patient and device selection,
and to improve outcomes and decrease complication rates for new innovative strategies. A review of the
published literature in this field is timely and relevant.
Recent findings
There has been a rapid evolution of using adult designed continuous flow VADS to support children and
adults with CHD (ACHD). Patient selection for patients with CHD is complex because of patient size and
anatomical diversity and, therefore, makes decision-making complex and unique when compared to
general adult practice. Outcomes for children depend on size and diagnosis with neonates with single
ventricle physiology being the highest risk candidates. This also holds true for ACHD, in which VAD
outcomes in patients with two ventricle physiology are comparable to non-ACHD patients.
Summary
In children, there is an increased use of continuous flow devices and a growing experience with outpatient
management. Patients with CHD especially when associated with single ventricle physiologies, remain a
challenge when it comes to MCS/VAD placement but successful durable VAD implantation with discharge
home has been reported.
Keywords
adult congenital heart disease, congenital heart disease, failing Fontan circulation, failing Glenn circulation,
pediatric ventricular assist device
INTRODUCTION
When selecting patients for ventricular assist device
(VAD) placement three groups can be distinguished:
adult patients with anatomic normal heart which
counts for the majority of VAD implants, pediatric
patients with anatomic normal hearts, and patients
with congenital heart disease (CHD) irrespectively
of age. VAD therapy in adults with anatomical nor-
mal hearts has developed as a standard treatment
option [1]. However, supporting pediatrics and CHD
patients is more challenging but a standard arm of
the care pathway in end-stage heart failure. The aim
of this manuscript is to review current advances in
the use of VAD in pediatrics and patients with CHD.
PEDIATRIC VENTRICULAR ASSIST DEVICE
SUPPORT IN PATIENTS WITH
ANATOMICALLY NORMAL HEARTS
Historically VADs have been used as bridge to trans-
plantation (BTT) or recovery in children. In the last
years, there has been an increase in use of mechani-
cal support strategies (MCS) in the pediatric popu-
lation mainly driven by the development of smaller
VADs, namely continuous flow VADs. This is
reflected by increasing implant numbers of contin-
uous flow devices especially in patients more than
25kgs body weight [2,3
&
,4,5] (see Fig. 1). With more
experience and improved outcomes a change in the
paradigm has set in; VADs are no longer viewed as
the last treatment option.
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Device selection
The following considerations are important in deter-
mining device selection:
(1) What is the underlying disease? What is causing
the failure?
Structural CHD (see section VAD/MCS in
patients with CHD) may be leading to failed
circulation or is it ‘simple‘ form of myocardial
failure.
(2) What is the predicted estimate of time that VAD
support will be needed?
In scenarios like myocarditis or postcardiotomy
heart failure support using a temporary VAD [6]
might be sufficient, whereas in more chronic
heart failure prolonged support time needing
durable devices might be needed.
(3) Which ventricle(s) requires support?
Does the patient appear to have biventricular
failure or is it only one ventricle that needs
support is a crucial factor for surgical implanta-
tion strategy and postoperative management.
(4) What is the patients weight and body surface
area (BSA)?
Size remains an important factor for device
selection in children when compared with
adults.
(5) Will the patient be able to be discharged or is
there something that will prevent discharge?
Using the answers to these questions, the medi-
cal team must select the proper device for the
patient and avoid patient-device size mismatch.
The current most used (adult designed) devices
are HeartMate II/III (Abbott Medical), Heartware
Ventricular Assist Device (HVAD) (Medtronic),
and in smaller numbers DuraHeart (Terumo Heart)
and Incor (Berlin Heart). There have been some
devices i.e., DeBakey VAD Child or VentrAssist
which are no longer available on the market. Devel-
opment of pediatric-specific continuous flow VADs,
such as the Infant Jarvik, the only remaining VAD
in the PUMPKIN trial, was granted conditional
approval for Investigational Device Exemption by
the US Food and Drug Administration on 30 Sep-
tember 2016 [7].
There is no doubt that the encouraging out-
comes in adult continuous flow VAD technology
has had a profound impact on its use in children.
It is generally accepted in adult-sized adolescents,
who need an isolated left ventricular assist device
(LVAD), that an implantable continuous flow
VAD is the most common type of device used
KEY POINTS
 In pediatrics and CHD, there is an increase use of
continuous flow devices and a growing experience with
outpatient management.
 New technologies (i.e., virtual implantation for VAD
placement in complex and small patients) and sharing
experiences will assist in determining the optimal
device–patient match which will lead to more
successful outcomes and ideally an increase in patients
discharged home.
 ACHD patients (two ventricle anatomy) provided with a
LVAD demonstrated similar survival compared with non-
ACHD patients with LVADs.
FIGURE 1. There is a distinct increase of continuous flow ventricular assist devices implantations especially in patients more
than 25-kgs body weight. Reproduced from [3&].
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[2,3
&
,5,8
&&
,9
&
,10]. It remains unclear what the size
cut off is for the use of these devices in smaller
children [11–14].
Each of the current continuous flow devices
(Heart Mate II/III, HVAD) in clinical practice have
their own approved age and BSA range which varies
but is around 1.2m2. Continuous flow devices dom-
inate now the field in children above 5 years (56%
between 6 and 10 years of age and reaching 90%
of older children) and outcomes seem to be non-
inferior to pulsatile devices [15]. LVAD placement
has been reported down to a BSA of 1m2
[8
&&
,16,17
&
,18
&
,19]. Below this range there are mixed
results concerning outcome and adverse even rates
[17
&
,18
&
] [European Registry for Patients with
Mechanical Circulatory Support (EUROMACS)
paper]. For a BSA below 0.6m2 the extracorporeal
pulsatile Berlin Heart EXCOR (Berlin Heart) remains
the golden standard [20–22]. The new available
Berlin Heart EXCOR 15-ml pump chamber seems
to close a gap for children less than 0.5m2 [23,24].
Overall children weighing less than 10kg still need
to be evaluated very carefully if they have CHD and/
or liver dysfunction because their outcomes are
inferior [25].
Emerging concepts
Prolonged support
Published survival as BTT or bridge to recovery with
pulsatile or continuous flow devices has been
reported as high as 97% [4,26] with 6-month sur-
vival rates above 80% [5]. The latest Pedimacs
reports 6-month mortality rate on device at 16%
and a transplantation rate of nearly 50%. So far no
pediatric report from the EUROMACS register is
published but data from an EUROMACS analysis
on intracorporeal continuous flow devices in chil-
dren refers to an 11% mortality on device at
12 months [28
&&
]. Despite this rather short duration
of support it has been shown that that renal func-
tion [27
&&
] can improve irrespectively of the device
used Berlin heart EXCOR, continuous flow VAD,
or temporary device). Although the proportion of
patients who develop neurological dysfunction after
implantation of pulsatile devices has been docu-
mented to be approximately 19–30%, the incidence
of cerebral strokes in children supported by contin-
uous flow VADs has not beenwell explored. A recent
report from EUROMACS suggests that it may be as
low as 0.1 events per patient-year [28
&&
].
Continuous flow devices have opened the doors
to the discharge of pediatric patients on VADs.
Whereas some years ago only a few centers reported
discharging pediatric patients on continuous flow
devices [19], nowadays reported numbers are
between 55 [2] and 72% [28
&&
] Most reports suggest
that children with a continuous flow VAD can be
safely discharged home with device malfunction
and arrhythmia being the most common adverse
events [29]. Now that children are discharged safely
the idea of chronic or prolonged therapy in children
is becoming a reality [9
&
,30,31]. Current experience
with VAD support intended for prolonged therapy
(>5 years on device) [9
&
] or destination therapy in
patients suffering from skeletal myopathies, such as
Duchenne disease have been reported [32,33]. How-
ever, the percentage of patients categorized as desti-
nation therapy remains low (2.1%) [2]. In pediatrics
the concept of destination therapy may be different
when compared to adult provider beliefs. Char et al.
suggested that ‘providers are reaching a point where
they can consider long-term VAD for patients with
contraindications to transplant that have the poten-
tial to improve, or even can be stabilized long
enough for future therapies to emerge [34]. In this
sense, destination therapy in children may become
more like a long bridge to decision, rather than the
adult concept of destination therapy as a true ‘des-
tination’ [34].
Recovery
It is interesting that although there is huge enthusi-
asm for home discharge and possibility of prolonged
support times there has been little investigation into
myocardial recovery in children when compared
with adults. This may stem from the lack of reports
on the number of children undergoing device for
myocardial recovery, the shorter support times com-
pared with adults and the adverse event profiles of
some of the available devices [2]. There is currently a
lack of standardized guidelines for echocardio-
graphic and hemodynamic criteria for LVAD
removal in pediatrics [35] but the pediatric patient
population may have great potential for recovery
[13]. Extrapolation from adult data may be difficult
as it has been shown that myocardial recovery has
significant differences when comparing pediatric
and adult cardiomyopathy [36,37]. For instance, a
comparison of pediatric and adult gene expression
changes with VAD support reveals approximately
40% of genes to be oppositely regulated, indicating
that the pediatric genetic response is distinct [38].
Intracorporeal biventricular assist
device/total artificial heart
The majority of implants in children are only for
isolated left ventricular (LV) support. However,
there is a certain percentage of patients who require
biventricular support with themost recent Pedimacs
Pediatric and (adult) congenital heart disease Schweiger et al.
1087-2418 Copyright  2018 Wolters Kluwer Health, Inc. All rights reserved. www.co-transplantation.com 3
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
CE: Tripti; MOT/230303; Total nos of Pages: 7;
MOT 230303
report suggesting 15% of patients were supported
with a biventricular assist device (BiVAD) and 2%
with a total artificial heart (TAH) [2]. Results for
biventricular support have been reported to be infe-
rior to LVAD only [39]. Although the Berlin Heart
EXCOR remains the ‘golden standard‘ for biventric-
ular support in children some centers have pub-
lished case series using two continuous flow VADs
in pediatrics with successful BTT with BSA as low as
0.6m2 [40,12,41,42]. There are even reports of using
two continuous flow VADs in a patient with Fontan
circulation with subsequent discharge home [43].
Morales et al. [44
&
] published the global experi-
ence using Syncardia TAH in 43 patients at least
21 years with positive outcome of 70% (60 days),
63% (90 days), and 58% (120 days). Owing to the
large footprint of the 70-ml TAH, a 50ml has now
become available for patients with BSA as low as
1.2m2. TAH placement using ‘virtual implantation’
may help assess device fit and has evolved as an
accepted preoperative planning tool [45].
VENTRICULAR ASSIST DEVICE/
MECHANICAL SUPPORT STRATEGIES
PATIENTS WITH CONGENITAL HEART
DISEASE
With the increase in the number of survivors fol-
lowing neonatal and infant palliative heart surgery
there have been an increase in the number of
patients developing end-stage failure. It is estimated
that 10–20% of patients with CHDwill require heart
transplantation at some point of their life. Patients
with CHD and end-stage heart failure that need VAD
support have worse outcomes when compared with
children with cardiomyopathy [25]. Patients, irre-
spectively of age, with CHD represent a unique and
difficult patient population to support with VAD/
MCS. Although some of these patients might need
postcardiotomy circulatory support until myo-
cardial recovery others may require a durable VAD
because of the absence of myocardial recovery.
Short-term extracorporeal devices like extracorpo-
real membrane oxygenation or short-term continu-
ous flow VADs are used more often in complex CHD
patients than durable VADs [46]. However, when
durable VAD support using the Berlin Heart EXCOR
is necessary it has been shown to be more successful
in children greater than 1 year of age when com-
pared with the neonatal and infant cohort [47
&&
].
Recently, Morales et al. reported the results of the
Berlin Heart EXCOR in patients with CHD [47
&&
].
One third of all EXCOR patients had CHD and of
these 30% had a univentricular physiology [47
&&
].
The report showed that durable VADs should be
used very cautiously in children suffering from
complex CHD below 1 year of age, especially
patients on previous extracorporeal membrane
oxygenation and those who had prior cardiac sur-
gery [47
&&
].
Mechanical support strategies in single
ventricle physiology
Trials investigating the use of MCS in patients with
single ventricle do not exist. Information largely
stems from small case series or single case reports.
These reports have revealed high mortality rates
(two or three patients dying prior to discharge
[48
&&
]) and adverse events, compared to with two
ventricular physiology [49]. There are multiple rea-
sons for these findings, it may be that the mecha-
nism of failure at different stages of surgical
palliation is not amendable to VAD support.
There is a variety of anatomical variations that
result in single ventricle physiology. In affected
newborns with a lack of pulmonary blood flow
the first step is to establish sufficient flow to the
pulmonary arteries (natural via patent ductus arte-
riosus or surgical creation of a shunt) and balance
this with maintenance of the cardiac output. In the
second stage, around 4–6 months of age, the crea-
tion of a superior cavopulmonary anastomosis
ensures blood flow to the pulmonary arteries (Glenn
operation) and in the third step (Fontan operation),
done around 2–4 years of age, the inferior vena cava
is anastomosed to the pulmonary artery (Fontan
circulation). Heart failure or circulatory failure can
occur during any of these three stages and remains a
challenge to manage. Feasibility of VAD support for
Glenn circulation has been proven to be [50] associ-
ated with persistent cyanosis resulting in exercise
intolerance, extensive collateralization and subop-
timal outcome [49,51]. Adachi et al. [52] suggested
to avoid long-standing cyanosis, completion of
the Fontan circulation should occur at the time
of VAD implantation when implanted in a Glenn
circulation.
Most often Fontan failure presents as a failing
Fontan circulation rather than isolated myocardial
dysfunction. The pathophysiology of failure tends
to be multifactorial reason [53,54]: with diastolic
dysfunction commonly observed; further, increased
pulmonary vascular resistance inhibits the venous
return and results, therefore, in a reduced systemic
preload, cardiac output, and the development of
collateral vessels in various locations. When the
systolic function is characteristically preserved cur-
rently available MCS devices are unable to support
the patient because they are designed to provide
systemic circulatory support, not cardiopulmonary
support. Consequently, hemodynamic support for
Thoracic transplantation
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failing Fontan circulation that is not solely because
of myocardial dysfunction is not yet well defined.
Various concepts for a pump in the cavopulmonary
position are under current research. Whereas some
of these concepts are specifically designed for sup-
port of the total cavopulmonary connection t
[55,56], others have reported the use of currently
available VADs [57–60]. Most of the proposed
designs do not constitute an option for implantable
long-term destination therapy for Fontan patients
because of their design or their size. Most notably,
these patients have a documented increased risk of
hepatic [61], neurologic, and respiratory complica-
tions associated with the use of MCS/VAD [62].
Despite these potential adverse events, durable
VAD implantation in Fontan patients is increasing
with some patients being discharge home [43,63–
65].
Population of adults with congenital heart
disease with two ventricle anatomy/
physiology
Owing to improved surgical techniques and periop-
erative treatment options deaths and hospitaliza-
tions in CHD have shifted from infancy to
adulthood. The population of adults with CHD
(ACHD) currently exceeds the number of children
with CHD in many western countries and the use of
durable VAD utilization in ACHD are becoming
more frequent [66]. In ACHDpatients suffering from
complex CHD heart failure remains the leading
causes for mortality and accounts for 20% of hospi-
tal admissions [67]. Adequate risk stratification
focusing on mortality and morbidity in this popu-
lation, whose heterogeneous pathophysiology
differs from that of the general heart failure popula-
tion, are still missing [68]. This explains in parts
why ACHD patients are less frequent implanted
with VADs compared to acquired disease patients
[69,70] and represent a small portion (<1%) of the
total Interagency Registry for Mechanically Assisted
Circulatory Support (INTERMACS) population [61].
One may link this to a higher published adverse
event and an increased mortality rate [61] which is
only partial true. The higher mortality rate is exclu-
sively attributable to ACHD patients on BiVAD/TAH
support. ACHD and non-ACHD patients with
LVADs demonstrated similar survival regardless of
cardiac anatomy [61]. The present data from Van-
derplyum et al. also suggest a possible role for
increased LVAD use as destination therapy in this
population patients as the median age of ACHD
patients provided with a VAD is significant lower
(16%) compared with non-ACHD patients [61].
In two ventricular circulations one has to dis-
tinguish if there is a systemic morphologic LV or
systemic morphologic right ventricle (RV). A sys-
temic morphologic RV is present in patients with
transposition of great arteries (TGA) with ventri-
cular-atrial and ventricular-arterial discordance
(congenital corrected TGA, congenital corrected
transposition of the great arteries) or surgical cor-
rected dextrp Transposition of the great arteries
(ventricular-arterial discordance) using atrial switch
procedure (Senning or Mustard operation). Nowa-
days the arterial switch operation (ASO), which fully
restores the correct anatomical structure of the
heart, has become the primary method of choice
for surgical correction. Before the ASO was applied
the ASO (Senning or Mustard operation) was done.
Many patients who have undergone ASOmay suffer
from end-stage heart failure of the systemic RV and
will benefit from VAD support [61,66,71]. Limited
data und numbers, however, make standardized
approaches difficult; i.e., device selection, implant-
ing location of the inflow cannula into systemic
morphologic RVs [61,72–75].
ACHD patients differed most notably from non-
ACHDpatients in expected ways, including younger
age, greater allosensitization, more RV dysfunction,
and unfavorable mediastinal anatomy at time of
device implantation. Most ACHD had multiple pre-
vious cardiac surgery and interventions, which adds
to the complexity of the surgical procedure at the
time of VAD placement. Additionally, aortopulmo-
nary collaterals increase the bleeding risk which
makes the operating field hard to visualize suffi-
ciently. Therefore, preoperative assessment includ-
ing sufficient imaging remains a crucial part of the
success. As recommended by the 2010 International
Society for Heart and Lung Transplantation guide-
lines all patients with CHD should have recent
imaging to access for the presence of shunts or
collateral vessels (Class 1, C) [1]. In patients with
complex CHD, atypical situs, or residual intraven-
tricular shunts who are not candidates for LV sup-
port should be considered for a TAH [1].
CONCLUSION
Availability and outcome of continuous flow devi-
ces in pediatrics has changed the field. The era of
pediatric continuous flow VAD support has begun.
[...] The popularization of continuous flow VADs
represents a paradigm change in the field‘[9
&
].
Patients with CHD especially those with single ven-
tricle physiology remains a challenging population.
In ACHD, LVAD patients with two ventricle physi-
ology outcomes are comparable to non-ACHD
Pediatric and (adult) congenital heart disease Schweiger et al.
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patients and an increasing permanent support can
be expected.
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